Drug intelligence / Profile preview

SM-001

Development stage: Phase 1
Lead developer: SarcoMed
Modality: Small Molecules
Administration: Oral

Overview

SM-001 is an investigational new drug formulated as a hot water decoction of two Peruvian plants, Banisteriopsis caapi and Psychotria viridis. It represents a standardized modern formulation of the ancient Amazonian botanical medicine, "ayahuasca." The drug contains several active biomarkers, including dimethyltryptamine, harmine, tetrahydroharmine, and harmaline, which are responsible for its psychoactive and therapeutic effects. It is currently being investigated for its potential in treating Major Depression and Post Traumatic Stress Disorder.

Other names: Ayahuasca analog

Targets

MAOA (Monoamine oxidase A)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on SM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM-001.

Explore the full profile